MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade
Wei Wang, Dong Han, Qinbo Cai and 10 more
Nature Communications · 2022
doi:10.1038/s41467-021-27921-1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
PI3K inhibitors have limited efficacy in triple negative breast cancer (TNBC). Here, the authors show that MAPK4 activates AKT independent of PI3K and thus promotes tumour growth in a subset of TNBC and that MAPK4 inhibition sensitizes to PI3K blockade in these tumours.’
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.